155 related articles for article (PubMed ID: 36635892)
1. Pediatric inflammatory myofibroblastic tumor of the bladder with ALK-FN1 fusion successfully treated by alectinib.
Fujiki T; Sakai Y; Ikawa Y; Takenaka M; Noguchi K; Kuroda R; Abe T; Nomura K; Sakai S; Wada T
Pediatr Blood Cancer; 2023 Apr; 70(4):e30172. PubMed ID: 36635892
[TBL] [Abstract][Full Text] [Related]
2. Inflammatory myofibroblastic tumor of the urinary bladder with FN1‑ALK gene fusion: A case report.
Son SM; Woo CG; Lee OJ; Kim YJ; Lee HC
Oncol Lett; 2023 Jun; 25(6):227. PubMed ID: 37153035
[TBL] [Abstract][Full Text] [Related]
3. Inflammatory Myofibroblastic Tumor of the Bladder With FN1-ALK Gene Fusion: Different Response to ALK Inhibition.
Reinhart S; Trachsel Y; Fritz C; Wagner U; Bode-Lesniewska B; John H; Pless M
Urology; 2020 Dec; 146():32-35. PubMed ID: 33007314
[TBL] [Abstract][Full Text] [Related]
4. Pseudosarcomatous myofibroblastic proliferations of the urinary bladder are neoplasms characterized by recurrent FN1-ALK fusions.
Acosta AM; Demicco EG; Dal Cin P; Hirsch MS; Fletcher CDM; Jo VY
Mod Pathol; 2021 Feb; 34(2):469-477. PubMed ID: 32908253
[TBL] [Abstract][Full Text] [Related]
5. Durable response to the ALK inhibitor alectinib in inflammatory myofibroblastic tumor of the head and neck with a novel SQSTM1-ALK fusion: a case report.
Honda K; Kadowaki S; Kato K; Hanai N; Hasegawa Y; Yatabe Y; Muro K
Invest New Drugs; 2019 Aug; 37(4):791-795. PubMed ID: 30790150
[TBL] [Abstract][Full Text] [Related]
6. FN1: a novel fusion partner of ALK in an inflammatory myofibroblastic tumor.
Ouchi K; Miyachi M; Tsuma Y; Tsuchiya K; Iehara T; Konishi E; Yanagisawa A; Hosoi H
Pediatr Blood Cancer; 2015 May; 62(5):909-11. PubMed ID: 25682942
[TBL] [Abstract][Full Text] [Related]
7. Inflammatory myofibroblastic tumor of the mesentery with a SQSTM1::ALK fusion responding to alectinib.
Sunga CGG; Higgins MS; Ricciotti RW; Liu YJ; Cranmer LD
Cancer Rep (Hoboken); 2023 Mar; 6(3):e1792. PubMed ID: 36754839
[TBL] [Abstract][Full Text] [Related]
8. Inflammatory Myofibroblastic Tumour of the Urinary Bladder in a Middle-Aged Man-A Case Report of an Unusual Localization of a Rare Tumour.
Prijovic N; Santric V; Babic U; Stankovic B; Acimovic M; Cekerevac M; Nikolic G; Cegar B
Medicina (Kaunas); 2023 Apr; 59(4):. PubMed ID: 37109749
[TBL] [Abstract][Full Text] [Related]
9. A case of inflammatory myofibroblastic tumor harboring EML4-ALK fusion with a brain metastasis responding to alectinib.
Sakoda S; Tanaka K; Koga Y; Mikumo H; Tsuchiya-Kawano Y; Harada E; Tamiya S; Okamoto I
Thorac Cancer; 2024 Feb; 15(5):415-418. PubMed ID: 38213097
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant crizotinib in ALK-rearranged inflammatory myofibroblastic tumor of the urinary bladder: A case report.
Nagumo Y; Maejima A; Toyoshima Y; Komiyama M; Yonemori K; Yoshida A; Fujimoto H
Int J Surg Case Rep; 2018; 48():1-4. PubMed ID: 29758320
[TBL] [Abstract][Full Text] [Related]
11. A case report: Pharmacology and resistance patterns of three generations of ALK inhibitors in metastatic inflammatory myofibroblastic sarcoma.
Parker BM; Parker JV; Lymperopoulos A; Konda V
J Oncol Pharm Pract; 2019 Jul; 25(5):1226-1230. PubMed ID: 29925295
[TBL] [Abstract][Full Text] [Related]
12. Durable Clinical Response to ALK Tyrosine Kinase Inhibitors in Epithelioid Inflammatory Myofibroblastic Sarcoma Harboring
Wang Z; Geng Y; Yuan LY; Wang MM; Ye CY; Sun L; Dai WP; Zang YS
Front Oncol; 2022; 12():761558. PubMed ID: 35237506
[TBL] [Abstract][Full Text] [Related]
13. Dramatic response to alectinib in inflammatory myofibroblastic tumor with anaplastic lymphoma kinase fusion gene.
Saiki M; Ohyanagi F; Ariyasu R; Koyama J; Sonoda T; Nishikawa S; Kitazono S; Yanagitani N; Horiike A; Ninomiya H; Ishikawa Y; Nishio M
Jpn J Clin Oncol; 2017 Dec; 47(12):1189-1192. PubMed ID: 28977547
[TBL] [Abstract][Full Text] [Related]
14. ALK inhibition in two emblematic cases of pediatric inflammatory myofibroblastic tumor: Efficacy and side effects.
Brivio E; Zwaan CM
Pediatr Blood Cancer; 2019 May; 66(5):e27645. PubMed ID: 30697903
[TBL] [Abstract][Full Text] [Related]
15. A novel fusion of HNRNPA1-ALK in inflammatory myofibroblastic tumor of urinary bladder.
Inamura K; Kobayashi M; Nagano H; Sugiura Y; Ogawa M; Masuda H; Yonese J; Ishikawa Y
Hum Pathol; 2017 Nov; 69():96-100. PubMed ID: 28504207
[TBL] [Abstract][Full Text] [Related]
16. ALK Gene Translocation in Inflammatory Myofibroblastic Tumor of the Urinary Bladder: A Case Report.
Takagi K; Takai M; Kameyama K; Horie K; Kikuchi M; Kato T; Mizutani K; Seike K; Tsuchiya T; Yasuda M; Yokoi S; Suzui N; Nakano M; Deguchi T
Urol Case Rep; 2015 Sep; 3(5):138-40. PubMed ID: 26793530
[TBL] [Abstract][Full Text] [Related]
17. Uterine inflammatory myofibroblastic tumor: First report of a ROS1 fusion.
Bennett JA; Wang P; Wanjari P; Diaz L; Oliva E
Genes Chromosomes Cancer; 2021 Dec; 60(12):822-826. PubMed ID: 34322931
[TBL] [Abstract][Full Text] [Related]
18. Recurrent uterine inflammatory myofibroblastic tumor previously managed as leiomyosarcoma has sustained response to alectinib.
Carballo EV; Pham TV; Turashvili G; Hanley K; Starbuck KD; Meisel JL
Gynecol Oncol Rep; 2022 Oct; 43():101062. PubMed ID: 36032811
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological analysis and outcomes of inflammatory myofibroblastic tumours of the urinary bladder.
Hensley PJ; Bree KK; Guo CC; Lobo N; Campbell MT; Pettaway CA; Kamat AM
BJU Int; 2022 Nov; 130(5):604-610. PubMed ID: 34773684
[TBL] [Abstract][Full Text] [Related]
20. Inflammatory Myofibroblastic Tumor of the Urinary Bladder: A Case Report.
Etani T; Naiki T; Nagai T; Iida K; Ando R; Naiki-Ito A; Kawai N; Tozawa K; Mizuno K; Okada A; Mogami T; Yasui T
Case Rep Oncol; 2016; 9(2):464-469. PubMed ID: 27721769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
